

Project Description and Pilot Study for A Pathologist-Annotated AI/ML Validation Dataset

Sarah Dudgeon (MPH) and Brandon Gallas (PhD)



FDA/CDRH/OSEL/Division of Imaging, Diagnostics, and Software Reliability

Collaborators: Si Wen, PhD, Matthew Hanna, MD, Rajendra Gupta, MD, Mohamed Amgad Tageldin, PhD, Menasi Sheih, PhD, Helei Marble, PhD, Richard Huang, MD, Markus Herrmann, MD PhD, Clifford H. Szu, Derek Tong, Bruce Weerness, MD, Denis Lastimort, MD, Anant Madabhushi, PhD, Evangelos Hyppoulas, PhD, Rajendra Singh, MD, Steven Hart, PhD, Joel Saltz, MD PhD, Roberto Salgado, MD *

“We are crowdsourcing pathologists to collect data (images + pathologist annotations) that can be qualified by the FDA/CDRH medical device development tool program (MDDT). If successful, the MDDT qualified data along with a statistical software package for data analysis would be available to any algorithm developer to be used to validate their algorithm performance in a submission to the FDA/CDRH.”

1 Set up Nested Data:

Slides / Regions of Interest
Tumor Infiltrating Lymphocytes (TILs)




2

Task 1: Label the ROI


Task 2: Indicate Visual TIL Assessment Eligibility

Task 3: Record % TILs





3


Digital Platforms:
PathPresenter, caMicroscope




Microscope Platform:
eEDAP





A. Analytical Validation



B. Clinical Validation: Independent Crossover



C. Clinical Validation: Sequential Study Design



SCAN ME

- Setting:**
- Breast cancer pathology biomarker
 - Artificial Intelligence for digital pathology
 - Need high quality validation

- Objectives:**
- Validation dataset of: Images + Slides + Annotations
 - Pursue CDRH Medical Device Development Tool (MDDT) for dataset

- Regulatory Impact:**
- Clarify issues related to validating algorithms.
 - Provide example for others to follow.

- Methods:**
- Reference standard: Noisy truth by pathologists.
 - Pathologist training
 - Multiple international clinical sites (generalizable results)
 - Multiple regions of interest (ROI) per case (correlated data)

- Statistical analyses must account for**
- Pathologist variability
 - Correlated ROIs